Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 538,046 |
|
|||||
| News | - | ||||||
| Day High | 1.16 | Low High |
|||||
| Day Low | 1.04 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Kronos Bio Inc | KRON | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.04 | 3.77% | 1.10 | 16:12:56 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.05 | 1.04 | 1.16 | 1.11 | 1.06 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,820 | 538,046 | $ 1.09 | $ 584,086 | - | 0.69 - 2.29 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:06:51 | formt | 200 | $ 1.10 | USD |
Kronos Bio Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 62.4M | 58.32M | - | 6.29M | -112.67M | -1.93 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Kronos Bio News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical KRON Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.7225 | 1.33 | 0.7151 | 1.08 | 1,650,502 | 0.3775 | 52.25% |
| 1 Month | 1.00 | 1.33 | 0.69 | 0.9752015 | 708,903 | 0.10 | 10.00% |
| 3 Months | 1.20 | 1.38 | 0.69 | 1.01 | 503,633 | -0.10 | -8.33% |
| 6 Months | 1.45 | 1.5053 | 0.69 | 1.06 | 372,036 | -0.35 | -24.14% |
| 1 Year | 1.69 | 2.29 | 0.69 | 1.20 | 322,232 | -0.59 | -34.91% |
| 3 Years | 26.05 | 27.15 | 0.69 | 5.46 | 308,988 | -24.95 | -95.78% |
| 5 Years | 28.29 | 39.605 | 0.69 | 8.85 | 294,647 | -27.19 | -96.11% |
Kronos Bio Description
| Kronos Bio Inc is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel cancer therapeutics designed to transform patient outcomes through a precision medicine strategy by targeting dysregulated transcription. |
